FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162888672> ?p ?o ?g. }

• W3162888672 endingPage "3149" @default.
• W3162888672 startingPage "3134" @default.
• W3162888672 abstract "Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell rescue, and maintenance. High-dose therapy with a DNA alkylating agent, melphalan, remains the primary drug for consolidation therapy in conjunction with autologous stem-cell transplantation; as such, melphalan resistance remains a relevant clinical challenge. Here, we describe a proteometabolomic approach to examine mechanisms of acquired melphalan resistance in two cell line models. Drug metabolism, steady-state metabolomics, activity-based protein profiling (ABPP, data available at PRIDE: PXD019725), acute-treatment metabolomics, and western blot analyses have allowed us to further elucidate metabolic processes associated with melphalan resistance. Proteometabolomic data indicate that drug-resistant cells have higher levels of pentose phosphate pathway metabolites. Purine, pyrimidine, and glutathione metabolisms were commonly altered, and cell-line-specific changes in metabolite levels were observed, which could be linked to the differences in steady-state metabolism of naïve cells. Inhibition of selected enzymes in purine synthesis and pentose phosphate pathways was evaluated to determine their potential to improve melphalan’s efficacy. The clinical relevance of these proteometabolomic leads was confirmed by comparison of tumor cell transcriptomes from newly diagnosed MM patients and patients with relapsed disease after treatment with high-dose melphalan and autologous stem-cell transplantation. The observation of common and cell-line-specific changes in metabolite levels suggests that omic approaches will be needed to fully examine melphalan resistance in patient specimens and define personalized strategies to optimize the use of high-dose melphalan." @default.
• W3162888672 created "2021-05-24" @default.
• W3162888672 creator A5002425392 @default.
• W3162888672 creator A5002876951 @default.
• W3162888672 creator A5003366587 @default.
• W3162888672 creator A5009123312 @default.
• W3162888672 creator A5010665082 @default.
• W3162888672 creator A5014350127 @default.
• W3162888672 creator A5017353282 @default.
• W3162888672 creator A5022286739 @default.
• W3162888672 creator A5035860017 @default.
• W3162888672 creator A5040771903 @default.
• W3162888672 creator A5051737909 @default.
• W3162888672 creator A5053572690 @default.
• W3162888672 creator A5062287754 @default.
• W3162888672 creator A5062691289 @default.
• W3162888672 creator A5068346169 @default.
• W3162888672 creator A5076018965 @default.
• W3162888672 creator A5076672524 @default.
• W3162888672 creator A5077383203 @default.
• W3162888672 creator A5086011649 @default.
• W3162888672 creator A5086603901 @default.
• W3162888672 date "2021-05-20" @default.
• W3162888672 modified "2023-09-26" @default.
• W3162888672 title "Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma" @default.
• W3162888672 cites W1965264508 @default.
• W3162888672 cites W1968252950 @default.
• W3162888672 cites W1975149488 @default.
• W3162888672 cites W1988180979 @default.
• W3162888672 cites W1989299822 @default.
• W3162888672 cites W1994053770 @default.
• W3162888672 cites W1999549312 @default.
• W3162888672 cites W1999574084 @default.
• W3162888672 cites W2000055901 @default.
• W3162888672 cites W2007483962 @default.
• W3162888672 cites W2009865521 @default.
• W3162888672 cites W2015154009 @default.
• W3162888672 cites W2019806781 @default.
• W3162888672 cites W2025013606 @default.
• W3162888672 cites W2044225326 @default.
• W3162888672 cites W2069074510 @default.
• W3162888672 cites W2072621169 @default.
• W3162888672 cites W2076896674 @default.
• W3162888672 cites W2080752012 @default.
• W3162888672 cites W2085827004 @default.
• W3162888672 cites W2087038842 @default.
• W3162888672 cites W2087630691 @default.
• W3162888672 cites W2093106295 @default.
• W3162888672 cites W2103289668 @default.
• W3162888672 cites W2107665951 @default.
• W3162888672 cites W2113667128 @default.
• W3162888672 cites W2125721471 @default.
• W3162888672 cites W2127192057 @default.
• W3162888672 cites W2128084036 @default.
• W3162888672 cites W2144058399 @default.
• W3162888672 cites W2146512944 @default.
• W3162888672 cites W2157720858 @default.
• W3162888672 cites W2169456326 @default.
• W3162888672 cites W2473984675 @default.
• W3162888672 cites W2490307663 @default.
• W3162888672 cites W2511571730 @default.
• W3162888672 cites W2537438555 @default.
• W3162888672 cites W2550414527 @default.
• W3162888672 cites W2560592054 @default.
• W3162888672 cites W2604776612 @default.
• W3162888672 cites W2624372404 @default.
• W3162888672 cites W2737964630 @default.
• W3162888672 cites W2746456353 @default.
• W3162888672 cites W2781388087 @default.
• W3162888672 cites W2789291925 @default.
• W3162888672 cites W2803664483 @default.
• W3162888672 cites W2904294860 @default.
• W3162888672 cites W2911188335 @default.
• W3162888672 cites W2919022600 @default.
• W3162888672 cites W2923914229 @default.
• W3162888672 cites W2936045790 @default.
• W3162888672 cites W2946698672 @default.
• W3162888672 cites W2973061408 @default.
• W3162888672 cites W2996752315 @default.
• W3162888672 cites W3012615408 @default.
• W3162888672 cites W3017057237 @default.
• W3162888672 cites W4294216483 @default.
• W3162888672 doi "https://doi.org/10.1021/acs.jproteome.1c00022" @default.
• W3162888672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34014671" @default.
• W3162888672 hasPublicationYear "2021" @default.
• W3162888672 type Work @default.
• W3162888672 sameAs 3162888672 @default.
• W3162888672 citedByCount "9" @default.
• W3162888672 countsByYear W31628886722021 @default.
• W3162888672 countsByYear W31628886722022 @default.
• W3162888672 countsByYear W31628886722023 @default.
• W3162888672 crossrefType "journal-article" @default.
• W3162888672 hasAuthorship W3162888672A5002425392 @default.
• W3162888672 hasAuthorship W3162888672A5002876951 @default.
• W3162888672 hasAuthorship W3162888672A5003366587 @default.
• W3162888672 hasAuthorship W3162888672A5009123312 @default.
• W3162888672 hasAuthorship W3162888672A5010665082 @default.
• W3162888672 hasAuthorship W3162888672A5014350127 @default.

• next